Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 6, 2022

Details for Patent: 9,539,218

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,539,218 protect, and when does it expire?

Patent 9,539,218 protects XARELTO and is included in one NDA.

Protection for XARELTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-six countries.

Summary for Patent: 9,539,218
Title:Prevention and treatment of thromboembolic disorders
Abstract: The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
Inventor(s): Misselwitz; Frank (Heidelberg, DE), Kubitza; Dagmar (Ratingen, DE), Park; Son-Mi (Wuppertal, DE), Wehling; Klaus (Wuppertal, DE)
Application Number:11/883,218
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,539,218
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,539,218

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-003 Nov 4, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,539,218

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05001893Jan 31, 2005
PCT Information
PCT FiledJanuary 19, 2006PCT Application Number:PCT/EP2006/000431
PCT Publication Date:August 03, 2006PCT Publication Number: WO2006/079474

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.